3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
45
Endometrial Neoplasms
10
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Progesterone Resistance
2
HR+/HER2- Breast Cancer
2
HR Positive HER2 Negative Advanced Breast Cancer
2
Endometrial Hyperplasia
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Obesity
1
Neoplasms by Site
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Carcinoma
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Leiomyoma
1
Infertility, Female
1
Infertility
1
Interventions
Fulvestrant
4
serabelisib
2
sapanisertib
2
ribociclib
2
palbociclib
2
tivozanib
1
pembrolizumab
1
olaparib
1
exemestane
1
abemaciclib
1
Tamoxifen
1
Secretin
1
STX-478
1
Radiotherapy
1
Pharmaceutical Preparations
1
Paclitaxel
1
Nivolumab
1
Metformin
1
Letrozole
1
Irinotecan
1
Imlunestrant
1
Gemcitabine
1
Carboplatin
1
CA-19-9 Antigen
1
Anastrozole
1
AZD1390
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hereditary Sensory and Autonomic Neuropathies
×
Letrozole
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled